Skip to main navigation
menu

Aclaris - Corp Menu

  • About Us »
    « Back
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Compliance
    • Contact
  • Research and Development »
    « Back
    • Drug Development Pipeline
    • Investigational Drug Candidates
    • Diseases and Conditions
    • Clinical Trials
    • Drug Discovery
    • Expanded Access
    • Investigator Initiated Studies
    • Publications
  • Partnerships
  • Careers
  • Citizenship »
    « Back
    • Scientist Development Program
    • Aclaris Support
  • Investors »
    « Back
    • Investor Overview
    • Stock Information
    • Press Releases
    • Events
    • Investor Presentations
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
    • Email Alerts

Aclaris - Extras Menu

  • Media resources
  • Contact us

Aclaris - Corp Menu

  • About Us »
    « Back
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Compliance
    • Contact
  • Research and Development »
    « Back
    • Drug Development Pipeline
    • Investigational Drug Candidates
    • Diseases and Conditions
    • Clinical Trials
    • Drug Discovery
    • Expanded Access
    • Investigator Initiated Studies
    • Publications
  • Partnerships
  • Careers
  • Citizenship »
    « Back
    • Scientist Development Program
    • Aclaris Support
  • Investors »
    « Back
    • Investor Overview
    • Stock Information
    • Press Releases
    • Events
    • Investor Presentations
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
    • Email Alerts

Aclaris - Investor Relations

  • Investor Overview
  • Stock Information
  • Press Releases
  • Events
  • SEC Filings
  • Corporate Governance
  • Investor Presentations
  • Investor FAQs
  • Email Alerts
Investor Contact
For investor related questions, please email
investors@aclaristx.com

Investor Overview

Stock quote
  
 
VOLUME:
View stock performance »

Minimum 15 minutes delayed. Source: LSEG

Investor Overview

Press Releases
November 12, 2026
Aclaris Therapeutics to Participate in the Jefferies Global Healthcare Conference
November 5, 2026
Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update
October 27, 2026
Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants
View all »
Events
Nov 16, 2026
10:30 AM GMT
Jefferies Global Healthcare Conference
Oct 27, 2026
8:00 AM EDT
ATI-052 Phase 1b POC Results Update
Sep 10, 2026
2:45 PM EDT
2026 Cantor Global Healthcare Conference
View all »
Feature Presentation
Corporate Update Presentation
August 2026 Corporate Presentation

Aclaris - Footer Menu

  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Fraudulent Activity Notice
© 2026 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.